CORDIS
EU research results

CORDIS

English EN
Control of the Ebola Oubreak by both innovative Ultrasensitive Detection of EBOV and therapy

Control of the Ebola Oubreak by both innovative Ultrasensitive Detection of EBOV and therapy

Objective

IF-EBOLA has been strategically designed to efficiently respond to critical needs required to control Ebola outbreak from spreading and prepare a therapeutic approach to save lives. The work involves two of the main EVD outbreak sites, Sierra Leone and Liberia. MDs, public health authorities and virus experts working on site, under ethical regulatory rules, will extend their collaboration to companies and institutions to form a consortium of outstanding complementary partners, sharing their innovative technological approaches for a common goal.
The main goal of our project is to contribute to provide innovative ultrasensitive diagnostics and therapeutic approaches for an early and accurate diagnostic for an early therapeutic treatment to control the epidemic and safe lives.

We have been obligated to modify and extend for one year our initial two-year period IF-EBOLA action program due to both major foreseen and unforeseen changes produced during this “non-emergency” period: consisting mainly now in 3 main actions: (i) Preclinical validation of the therapeutic equine anti-Ebola antibodies; (ii) Clinical validation of the ultrasensitive detection (iii) homeostasis (“pathology”) profiling of patients and survivors.
Originally (“emergency period”) IF-EBOLA included 2 phases: (I) a phase of preparation including, ethical authorizations, antibody production, technical and field organization as well as the beginning a follow-up of the homeostatic profile of contacts early-EBOV diagnosed and self-cured convalescent individuals in the absence of existing treatment, (with an ultrasensitive detection method of pernicious microorganisms, from the EC USDEP project qualified as a European success story “USDEP” project in 2010 by the EC-Project Officer) and (II) phase of a clinical study using a wide validated approach revisited with an innovative concept (strongly supported EC/EMA-WHO), we propose to carry out an experimental passive-immune therapy based on neutralizing capacity of horse anti-EBOV polyclonal F(ab’)2 on early-diagnosed patients to impact and reduce their pre-existing viremia, their mortality, the evolution of their homeostasis profile, during and after this treatment (once patients become convalescents). The homeostasis status evolution will help to generate high quality scientific data to understand the EVD, the effect of this therapy and cure parameters characterized at 3 different levels: immune (transcriptomes, NGS, metagenomics); infectious (other than EBOV, DNA arrays), and EBOV diversity (sequencing and metagenomics).
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT

Address

Boulevard De Dunkerque 44 Cs 90009
13572 Marseille

France

Activity type

Research Organisations

EU Contribution

€ 360 895

Participants (9)

Sort alphabetically

Sort by EU Contribution

Expand all

BEN-GURION UNIVERSITY OF THE NEGEV

Israel

EU Contribution

€ 199 350

ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE LAZZARO SPALLANZANI-ISTITUTO DI RICOVERO E CURA A CARATTERE SCIENTIFICO

Italy

EU Contribution

€ 52 700

INSTITUT PASTEUR

France

EU Contribution

€ 127 075

FABENTECH

France

EU Contribution

€ 972 750

UNIVERSITY OF MANITOBA

Canada

METABIOTA INC

United States

EU Contribution

€ 100 000

ORION INTEGRATED BIOSCIENCES INC.

United States

EU Contribution

€ 135 000

ABSISKEY

France

EU Contribution

€ 45 000

ABSISKEY CP

France

Project information

Grant agreement ID: 666102

Status

Closed project

  • Start date

    1 November 2014

  • End date

    31 October 2017

Funded under:

H2020-EU.3.1.

  • Overall budget:

    € 2 037 770

  • EU contribution

    € 1 992 770

Coordinated by:

INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT

France